1. Home
  2. CNVS vs IFRX Comparison

CNVS vs IFRX Comparison

Compare CNVS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNVS
  • IFRX
  • Stock Information
  • Founded
  • CNVS 2000
  • IFRX 2007
  • Country
  • CNVS United States
  • IFRX Germany
  • Employees
  • CNVS N/A
  • IFRX N/A
  • Industry
  • CNVS Consumer Electronics/Video Chains
  • IFRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNVS Consumer Discretionary
  • IFRX Health Care
  • Exchange
  • CNVS Nasdaq
  • IFRX Nasdaq
  • Market Cap
  • CNVS 64.1M
  • IFRX 53.5M
  • IPO Year
  • CNVS 2003
  • IFRX 2017
  • Fundamental
  • Price
  • CNVS $3.36
  • IFRX $1.43
  • Analyst Decision
  • CNVS Buy
  • IFRX Strong Buy
  • Analyst Count
  • CNVS 1
  • IFRX 5
  • Target Price
  • CNVS $10.00
  • IFRX $7.40
  • AVG Volume (30 Days)
  • CNVS 163.1K
  • IFRX 492.5K
  • Earning Date
  • CNVS 11-13-2025
  • IFRX 11-07-2025
  • Dividend Yield
  • CNVS N/A
  • IFRX N/A
  • EPS Growth
  • CNVS N/A
  • IFRX N/A
  • EPS
  • CNVS 0.13
  • IFRX N/A
  • Revenue
  • CNVS $80,173,000.00
  • IFRX $191,224.00
  • Revenue This Year
  • CNVS $0.76
  • IFRX N/A
  • Revenue Next Year
  • CNVS N/A
  • IFRX $1,216.24
  • P/E Ratio
  • CNVS $25.16
  • IFRX N/A
  • Revenue Growth
  • CNVS 77.07
  • IFRX 54.36
  • 52 Week Low
  • CNVS $0.98
  • IFRX $0.71
  • 52 Week High
  • CNVS $7.39
  • IFRX $2.82
  • Technical
  • Relative Strength Index (RSI)
  • CNVS 35.55
  • IFRX 55.06
  • Support Level
  • CNVS $3.33
  • IFRX $1.29
  • Resistance Level
  • CNVS $3.52
  • IFRX $1.44
  • Average True Range (ATR)
  • CNVS 0.16
  • IFRX 0.14
  • MACD
  • CNVS 0.07
  • IFRX -0.00
  • Stochastic Oscillator
  • CNVS 33.93
  • IFRX 48.84

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: